ESPR Mid-Q1 '19 Update


ESPR entered into a major partnership agreement with Daichi Sankyo Europe to commercialize bempadoic acid (BA), its oral drug for lowering LDL-C for patients who are on maximum statins, in Europe. The market did not react favorably to the deal likely because Daichi is not a top 3 worldwide cardio company, but we think the deal is a good one for ESPR and further validates the value of BA. You can see more details on our Catalyst Calendar entry at https://www.ampbioresearch.com/member-catalyst-calendar.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon